ATP III update targets high-risk patients, statins market to benefit?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1447, 2004-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ATP III update targets high-risk patients, statins market to benefit?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 458, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout: Was its Withdrawal from the Market in the Best Interest of Patients?

By Lee Ming-Han H. Graham Garry G. Williams Kenneth M. Day Richard O.

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 643-665

Adis International

Access to resources Recommend Favorite

Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?

By Shantsila Eduard Watson Timothy Lip Gregory Y.H.

PharmacoEconomics, Vol. 24, Iss. 10, 2006-01 ,pp. : 1035-1038

Adis International

Access to resources Recommend Favorite

On-treatment apolipoprotein levels: predictive benefit?

Inpharma, Vol. 1, Iss. 1271, 2001-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Can tumour response predict a survival benefit?

Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite